NeuroOne (NMTC) CEO disposes shares to cover tax obligations

Rhea-AI Filing Summary

NEUROONE MEDICAL TECHNOLOGIES Corp CEO and President David A. Rosa reported a Form 4 transaction involving company common stock. On February 18, 2026, he disposed of 71,325 shares at $0.68 per share in a tax-withholding disposition related to equity compensation, not an open-market sale. After this transaction, he directly owned 1,082,590 common shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rosa David A

(Last) (First) (Middle)

7599 ANAGRAM DR.

(Street)

EDEN PRAIRIE MN 55344

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEUROONE MEDICAL TECHNOLOGIES Corp [ NMTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and President

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/18/2026		F		71,325	D	$0.68	1,082,590	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Emily Johns, by Power of Attorney	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did NMTC CEO David A. Rosa report on this Form 4?

David A. Rosa reported a tax-related share disposition on this Form 4. He used 71,325 shares of NEUROONE MEDICAL TECHNOLOGIES common stock to cover tax obligations tied to equity compensation, rather than selling shares in an open-market transaction.

How many NMTC shares were involved in David A. Rosa’s tax-withholding disposition?

The transaction involved 71,325 shares of NEUROONE MEDICAL TECHNOLOGIES common stock. These shares were disposed of to satisfy tax liabilities associated with equity awards, as indicated by transaction code F, which denotes payment of exercise price or tax liability by delivering securities.

What price per share was used in David A. Rosa’s NMTC Form 4 transaction?

The Form 4 shows a transaction price of $0.68 per share for the 71,325 NEUROONE MEDICAL TECHNOLOGIES common shares. This price is used for reporting the value of the tax-withholding disposition and does not necessarily represent an open-market trade price.

How many NMTC shares does David A. Rosa own after this Form 4 transaction?

Following the reported transaction, David A. Rosa directly owned 1,082,590 shares of NEUROONE MEDICAL TECHNOLOGIES common stock. This post-transaction amount reflects his remaining direct holdings after using 71,325 shares to cover tax liabilities on equity compensation.

Does this NMTC Form 4 show an open-market sale by the CEO?

The filing indicates a tax-withholding disposition, not an open-market sale. Transaction code F and the description specify that 71,325 shares were delivered to pay an exercise price or tax liability tied to equity awards, rather than being sold on the open market.

Is David A. Rosa’s ownership in NMTC reported as direct or indirect after the transaction?

The Form 4 reports his ownership as direct after the transaction. The total of 1,082,590 NEUROONE MEDICAL TECHNOLOGIES common shares is classified with a direct ownership code, indicating they are held directly in his name rather than through an intermediary entity.